Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NYSE:ANRO

Alto Neuroscience Q1 2026 Earnings Report

Alto Neuroscience logo
$24.74 -0.71 (-2.79%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alto Neuroscience EPS Results

Actual EPS
N/A
Consensus EPS
-$0.56
Beat/Miss
N/A
One Year Ago EPS
N/A

Alto Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alto Neuroscience Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Alto Neuroscience Earnings Headlines

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
May 4 at 8:03 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260504596889/en/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-major-depressive-disorder-at-sobp-annual-meeting/
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
April 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750217
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
April 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260421195849/en/alto-neuroscience-initiates-phase-2b-trial-of-alto-207-in-treatment-resistant-depression/
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO)
April 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1128266/chardan-capital-remains-a-buy-on-alto-neuroscience-inc-anro/
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session
April 2, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/alto-neuroscience-immunovant-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session/ar-AA200uHd
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.

View Alto Neuroscience Profile
Earnings Tools